PurMinds Files Q2 Financials, PCAOB Audit
Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026
The submission of financials and the ongoing United States — Public Company Accounting Oversight Board audit by CSTS Enterprises, Inc. are positive steps towards increased transparency and potential uplisting to higher market tiers like OTCQB Venture Market or OTC Markets Group. This could attract more institutional investors and improve the company's stock liquidity and valuation. The capital raises and R&D investments indicate a focus on growth, which could positively impact the biotechnology and pharmaceutical industries.
CSTS Enterprises, Inc., a clinical-stage precision medicine and neuroscience company, announced the formal submission of its fiscal second-quarter financials for the period ended March 31, 2026, on OTC Markets Group. The company is currently undergoing a United States — Public Company Accounting Oversight Board audit, led by CFO and COO Angelo Pizzuto, which is a regulatory requirement for its planned uplisting to the OTCQB Venture Market or OTC Markets Group market tiers. This move aims to enhance institutional-grade transparency and accelerate its capital markets strategy. The audit process, which began on May 6, 2026, is expected to conclude by the end of June or early July 2026. CSTS Enterprises, Inc. also reported significant financial and corporate highlights, including the cancellation of legacy shares and liabilities, over $2.25 million in private capital raised, and $350,400 allocated to R&D, including a $250,000 licensing fee to SpectroChip Global Inc. for diagnostic platform rights. CEO Janet Qi and CFO Angelo Pizzuto emphasized the company's shift from corporate restructuring to a high-growth public market phase.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard